{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:48:41Z","timestamp":1789451321529,"version":"build-2803163510"},"reference-count":154,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013360","name":"Invest Northern Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013360","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.neuroscience.2026.01.038","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:01:08Z","timestamp":1769702468000},"page":"63-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Therapeutic efficacy of synthetic analogues of gut hormones in a mouse model of Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"600","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0712-8341","authenticated-orcid":false,"given":"Paul","family":"Denver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca T.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor A.","family":"Gault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3906-1172","authenticated-orcid":false,"given":"Paula L.","family":"McClean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2026.01.038_b0005","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1074\/jbc.M113.497909","article-title":"Cognitive deficits and disruption of neurogenesis in a mouse model of apolipoprotein E4 domain interaction","volume":"289","author":"Adeosun","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0010","doi-asserted-by":"crossref","first-page":"12334","DOI":"10.1074\/jbc.M110414200","article-title":"alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells","volume":"277","author":"Ahn","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0015","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1177\/002215540004801205","article-title":"Localization of xenin-immunoreactive cells in the duodenal mucosa of humans and various mammals","volume":"48","author":"Anlauf","year":"2000","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.neulet.2015.06.014","article-title":"How demanding is the brain on a reversal task under day and night conditions?","volume":"600","author":"Arias","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0025","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neurobiolaging.2005.10.017","article-title":"Effects of Alzheimer's peptide and alpha1-antichymotrypsin on astrocyte gene expression","volume":"28","author":"Baker","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0035","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0040","doi-asserted-by":"crossref","unstructured":"Batista, S. J., Still, K. M., Johanson, D., Thompson, J. A., O\u2019brien, C. A., Lukens, J. R. & Harris, T. H. 2020. Gasdermin-D-dependent IL-1<em>\u03b1<\/em> release from microglia promotes protective immunity during chronic <em>Toxoplasma gondii<\/em> infection. bioRxiv, 2020.01.22.915652.","DOI":"10.1038\/s41467-020-17491-z"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0045","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI57256","article-title":"An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers","volume":"122","author":"Bomfim","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0050","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI57256","article-title":"An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated A\u03b2 oligomers","volume":"122","author":"Bomfim","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0055","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.neulet.2009.09.057","article-title":"Alpha1-antichymotrypsin induces TNF-alpha production and NF-kappaB activation in the murine N9 microglial cell line","volume":"467","author":"Braghin","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0060","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/WNR.0000000000000548","article-title":"A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain","volume":"27","author":"Cao","year":"2016","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0065","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3233\/JAD-2009-1155","article-title":"Insulin is a two-edged knife on the brain","volume":"18","author":"Cardoso","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.741923","article-title":"Liraglutide reduces vascular damage, neuronal loss, and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes","volume":"13","author":"Carranza-Naval","year":"2021","journal-title":"Front. Aging Neurosci."},{"issue":"Suppl 2","key":"10.1016\/j.neuroscience.2026.01.038_b0075","first-page":"78","article-title":"Pathophysiology of diabetes mellitus type 2: beyond the duo \u201cinsulin resistance-secretion deficit\u201d","volume":"28","author":"Carrera Boada","year":"2013","journal-title":"Nutr. Hosp."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0080","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1007\/s11064-017-2250-8","article-title":"Liraglutide improves water maze learning and memory performance while reduces hyperphosphorylation of tau and neurofilaments in APP\/PS1\/Tau triple transgenic mice","volume":"42","author":"Chen","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0085","doi-asserted-by":"crossref","first-page":"40624","DOI":"10.1074\/jbc.M506069200","article-title":"The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity","volume":"280","author":"Cisse","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0090","first-page":"G190","article-title":"Relaxant effect of xenin on rat ileum is mediated by apamin-sensitive neurotensin-type receptors","volume":"272","author":"Clemens","year":"1997","journal-title":"Am. J. Phys. Anthropol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0095","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","article-title":"Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial","volume":"72","author":"Coric","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113723","article-title":"A GIP\/xenin hybrid in combination with exendin-4 improves metabolic status in db\/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice","volume":"171","author":"Craig","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41583-022-00558-9","article-title":"Impaired insulin signalling and allostatic load in Alzheimer disease","author":"de Felice","year":"2022","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/156720512799015037","article-title":"Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease","volume":"9","author":"De la Monte","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0125","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.cell.2014.10.016","article-title":"Lessons from a failed gamma-secretase Alzheimer trial","volume":"159","author":"De Strooper","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0130","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.brainres.2017.07.009","article-title":"Butyrylcholinesterase-knockout reduces fibrillar beta-amyloid and conserves (18)FDG retention in 5XFAD mouse model of Alzheimer's disease","volume":"1671","author":"Debay","year":"2017","journal-title":"Brain Res."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0135","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","article-title":"Peripheral anti-a beta antibody alters CNS and plasma a beta clearance and decreases brain a beta burden in a mouse model of Alzheimer's disease","volume":"98","author":"Demattos","year":"2001","journal-title":"PNAS"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0140","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/dom.13210","article-title":"Sustained high-fat diet modulates inflammation, insulin signalling and cognition in mice and a modified xenin peptide ameliorates neuropathology in a chronic high-fat model","volume":"20","author":"Denver","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21051746","article-title":"Liraglutide protects against brain amyloid-\u03b2(1-42) accumulation in female mice with early Alzheimer's disease-like pathology by partially rescuing oxidative\/nitrosative stress and inflammation","volume":"21","author":"Duarte","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0150","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neuroscience.2012.10.045","article-title":"The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP\/PS1 mouse model of Alzheimer's disease","volume":"228","author":"Duffy","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0155","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1370\/afm.3050","article-title":"Clinically important benefits and harms of monoclonal antibodies targeting amyloid for the treatment of alzheimer disease: a systematic review and meta-analysis","volume":"22","author":"Ebell","year":"2024","journal-title":"Ann. Fam. Med."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0160","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nm1555","article-title":"Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease","volume":"13","author":"el Khoury","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0165","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1152\/jn.00866.2010","article-title":"Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis","volume":"105","author":"Faivre","year":"2011","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0170","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ejphar.2011.11.007","article-title":"Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice","volume":"674","author":"Faivre","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0175","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3233\/JAD-121888","article-title":"D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model","volume":"35","author":"Faivre","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0180","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/alzrt174","article-title":"Neuroprotective effects of D-Ala(2)GIP on Alzheimer's disease biomarkers in an APP\/PS1 mouse model","volume":"5","author":"Faivre","year":"2013","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0185","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13063-019-3259-x","article-title":"Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)","volume":"20","author":"Femminella","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0190","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neuropharm.2018.02.012","article-title":"Two novel dual GLP-1\/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease","volume":"133","author":"Feng","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0195","doi-asserted-by":"crossref","DOI":"10.1111\/jne.12959","article-title":"Brain insulin, insulin-like growth factor 1 and glucagon-like peptide 1 signalling in Alzheimer's disease","volume":"33","author":"Ferreira","year":"2021","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0200","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7326\/M17-1529","article-title":"Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical alzheimer-type dementia: a systematic review","volume":"168","author":"Fink","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102019","article-title":"The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP\/PS1 mice","volume":"89","author":"Forny Germano","year":"2024","journal-title":"Mol. Metab."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0210","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neurobiolaging.2018.11.008","article-title":"Intranasal insulin activates Akt2 signaling pathway in the hippocampus of wild-type but not in APP\/PS1 Alzheimer model mice","volume":"75","author":"Gabbouj","year":"2019","journal-title":"Neurobiol. Aging"},{"issue":"Suppl 2","key":"10.1016\/j.neuroscience.2026.01.038_b0215","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.2337\/dc11-s231","article-title":"Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability","volume":"34","author":"Garber","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0220","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1152\/jn.01161.2007","article-title":"Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid","volume":"99","author":"Gault","year":"2008","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0225","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00592-014-0681-0","article-title":"Xenin-25[Lys13PAL]: a novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential","volume":"52","author":"Gault","year":"2015","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0230","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0235","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2008.01.050","article-title":"Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies","volume":"585","author":"Gerozissis","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0240","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0245","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.clinbiochem.2007.03.026","article-title":"The inflammation-sensitive protein alpha 1-anti-chymotrypsin neutralizes fibrillar aggregation and cytotoxicity of the beta-amyloid peptide more effectively than alpha 1-antitrypsin","volume":"40","author":"Giunta","year":"2007","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0250","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharep.2015.07.006","article-title":"Therapeutic strategies for Alzheimer's disease in clinical trials","volume":"68","author":"Godyn","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0255","doi-asserted-by":"crossref","first-page":"17213","DOI":"10.1073\/pnas.0508575102","article-title":"Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent","volume":"102","author":"Greig","year":"2005","journal-title":"PNAS"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0260","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1185\/03007990152673800","article-title":"A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase","volume":"17","author":"Greig","year":"2001","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0265","doi-asserted-by":"crossref","unstructured":"Hampel, H., Vassar, R., De Strooper, B., Hardy, J., Willem, M., Singh, N., Zhou, J., Yan, R., Vanmechelen, E., De Vos, A., Nistic\u00f2, R., Corbo, M., Imbimbo, B. P., Streffer, J., Voytyuk, I., Timmers, M., Tahami Monfared, A. A., Irizarry, M., Albala, B., Koyama, A., Watanabe, N., Kimura, T., Yarenis, L., Lista, S., Kramer, L. & Vergallo, A. 2020. The \u03b2-Secretase BACE1 in Alzheimer's Disease. Biol Psychiatry.","DOI":"10.1016\/j.biopsych.2020.02.001"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0270","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.neurobiolaging.2012.04.009","article-title":"Liraglutide protects against amyloid-beta protein-induced impairment of spatial learning and memory in rats","volume":"34","author":"Han","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0275","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1185\/03007995.2014.939167","article-title":"Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings","volume":"30","author":"Henley","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0280","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0285","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.neuropharm.2018.11.002","article-title":"Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of beta-amyloid pathology","volume":"144","author":"Holubova","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0290","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0295","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.peptides.2005.08.003","article-title":"Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL37) in normal mice","volume":"27","author":"Irwin","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0300","article-title":"The neural basis of reversal learning: an updated perspective","author":"Izquierdo","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155307","article-title":"The effect of a High-Fat Diet on Brain Plasticity, Inflammation and Cognition in Female ApoE4-knockin and ApoE-knockout mice","volume":"11","author":"Janssen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0310","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21051725","article-title":"Liraglutide suppresses tau hyperphosphorylation, amyloid beta accumulation through regulating neuronal insulin signaling and BACE-1 activity","volume":"21","author":"Jantrapirom","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0315","doi-asserted-by":"crossref","DOI":"10.1002\/jnr.70046","article-title":"Alzheimer's disease and frontotemporal dementia: a review of pathophysiology and therapeutic approaches","volume":"103","author":"Kelliny","year":"2025","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0320","doi-asserted-by":"crossref","DOI":"10.1111\/jne.12433","article-title":"Deciphering brain insulin receptor and IGF1 receptor signalling","author":"Kleinridders","year":"2016","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0325","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/0192623310387619","article-title":"Microglia: key innate immune cells of the brain","volume":"39","author":"Kofler","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0330","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/alz.12286","article-title":"ENGAGE and EMERGE: Truth and consequences?","volume":"17","author":"Kuller","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0335","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ejmech.2018.02.035","article-title":"Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead","volume":"148","author":"Kumar","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0340","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1017\/S1461145705005833","article-title":"Targeting acetylcholinesterase and butyrylcholinesterase in dementia","volume":"9","author":"Lane","year":"2006","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0345","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbr.2010.02.038","article-title":"Effects of neurotensin in amygdaloid spatial learning mechanisms","volume":"210","author":"Laszlo","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0350","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.bbr.2011.08.041","article-title":"The role of neurotensin in passive avoidance learning in the rat central nucleus of amygdala","volume":"226","author":"Laszlo","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0355","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1505","article-title":"The novel GLP-1\/GIP analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD","volume":"10","author":"Li","year":"2020","journal-title":"Brain Behav."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0360","article-title":"Neurotensin receptor 1 gene (NTSR1) polymorphism is associated with working memory","volume":"6","author":"Li","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0365","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neuroimage.2012.09.077","article-title":"The NTSR1 gene modulates the association between hippocampal structure and working memory performance","volume":"75","author":"Li","year":"2013","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0370","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/0023677215615269","article-title":"Sex differences between APPswePS1dE9 mice in A-beta accumulation and pancreatic islet function during the development of Alzheimer's disease","volume":"50","author":"Li","year":"2016","journal-title":"Lab Anim."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0375","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neuropharm.2015.10.002","article-title":"Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model","volume":"101","author":"Li","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0380","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13195-015-0137-y","article-title":"Modulation of Abeta42 in vivo by gamma-secretase modulator in primates and humans","volume":"7","author":"Ling","year":"2015","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0385","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12017-012-8199-5","article-title":"The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer's disease","volume":"15","author":"Long-Smith","year":"2013","journal-title":"NeuroMol. Med."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113222","article-title":"GLP-1 analogue liraglutide attenuates CIH-induced cognitive deficits by inhibiting oxidative stress, neuroinflammation, and apoptosis via the Nrf2\/HO-1 and MAPK\/NF-\u03baB signaling pathways","volume":"142","author":"Lv","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0395","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1507\/endocrj.EJ23-0723","article-title":"Liraglutide improves cognition function in streptozotocin-induced diabetic rats by downregulating \u03b2-secretase and \u03b3-secretase and alleviating oxidative stress in HT-22 cells","volume":"72","author":"Ma","year":"2025","journal-title":"Endocr. J."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0400","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/acel.12498","article-title":"Intranasal insulin alleviates cognitive deficits and amyloid pathology in young adult APPswe\/PS1dE9 mice","volume":"15","author":"Mao","year":"2016","journal-title":"Aging Cell"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0405","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bcp.2012.04.015","article-title":"Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25","volume":"84","author":"Martin","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0410","doi-asserted-by":"crossref","DOI":"10.1177\/1533317520953041","article-title":"The dual GLP-1\/GIP Receptor Agonist DA4-JC shows Superior protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP\/PS1 Mouse Model of Alzheimer's Disease","volume":"35","author":"Maskery","year":"2020","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0415","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neuropharm.2014.07.015","article-title":"Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer\u2019s disease","volume":"86","author":"McClean","year":"2014","journal-title":"Neuropharmacology"},{"issue":"Pt A","key":"10.1016\/j.neuroscience.2026.01.038_b0420","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuropharm.2013.08.005","article-title":"Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP\/PS1 mice, a model of Alzheimer's disease","volume":"76","author":"Mcclean","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0425","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbr.2015.07.024","article-title":"Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP\/PS1 mice","volume":"293","author":"McClean","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0430","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease","volume":"31","author":"McClean","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0435","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3233\/JPD-200002","article-title":"Clinical Trial highlights - GLP-1 agonists","volume":"10","author":"McFarthing","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0440","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.brainres.2012.07.029","article-title":"Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B\/16 mouse brain","volume":"1473","author":"McGovern","year":"2012","journal-title":"Brain Res."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0445","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of Lixisenatide in Early Parkinson's Disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0450","doi-asserted-by":"crossref","first-page":"30303","DOI":"10.1074\/jbc.M114.568212","article-title":"Methylene blue modulates beta-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice","volume":"289","author":"Mori","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0455","doi-asserted-by":"crossref","first-page":"40443","DOI":"10.1074\/jbc.M111.280495","article-title":"ADAM9 inhibition increases membrane activity of ADAM10 and controls alpha-secretase processing of amyloid precursor protein","volume":"286","author":"Moss","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0460","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.1523\/JNEUROSCI.0299-11.2011","article-title":"CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease","volume":"31","author":"Naert","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0465","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jmcb\/mjt028","article-title":"A deficiency in CCR2+ monocytes: the hidden side of Alzheimer's disease","volume":"5","author":"Naert","year":"2013","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0470","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0475","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0480","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13024-015-0033-8","article-title":"A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-beta and neuroinflammation in APP transgenic mice","volume":"10","author":"Neumann","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0485","article-title":"Intranasal insulin for improving cognitive function in multiple sclerosis","volume":"e00581","author":"Newsome","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0490","doi-asserted-by":"crossref","first-page":"44471","DOI":"10.1074\/jbc.M112.422402","article-title":"Contrasting effects of alpha-synuclein and gamma-synuclein on the phenotype of cysteine string protein alpha (CSPalpha) null mutant mice suggest distinct function of these proteins in neuronal synapses","volume":"287","author":"Ninkina","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0495","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1523\/JNEUROSCI.4920-04.2005","article-title":"Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation","volume":"25","author":"Nyberg","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0500","doi-asserted-by":"crossref","first-page":"16419","DOI":"10.1523\/JNEUROSCI.3317-10.2010","article-title":"Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits","volume":"30","author":"Oliveira","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0505","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020860","article-title":"Liraglutide has anti-inflammatory and anti-amyloid properties in streptozotocin-induced and 5xFAD mouse models of Alzheimer's Disease","volume":"22","author":"Paladugu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058784","article-title":"Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model","volume":"8","author":"Parthsarathy","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0515","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bcp.2018.07.021","article-title":"Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential","volume":"155","author":"Pathak","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0520","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16049","article-title":"Anti-amyloid antibody treatments for Alzheimer's disease","volume":"31","author":"Perneczky","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0525","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ejphar.2010.10.059","article-title":"Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice","volume":"650","author":"Porter","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0530","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1463-1326.2010.01259.x","article-title":"Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance","volume":"12","author":"Porter","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0535","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ijo.2012.91","article-title":"Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob\/ob mice","volume":"37","author":"Porter","year":"2013","journal-title":"Int. J. Obes. (Lond)"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0540","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.regpep.2010.07.101","article-title":"The glucagon-like peptide-1 agonist Liraglutide improves memory and learning in obese-diabetic mice","volume":"164","author":"Porter","year":"2010","journal-title":"Regul. Pept."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0545","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejphar.2016.04.052","article-title":"Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3beta pathway in an amyloid beta protein induced alzheimer disease mouse model","volume":"783","author":"Qi","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0550","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","article-title":"Alzheimer's disease","volume":"362","author":"Querfurth","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0555","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-2008-13309","article-title":"Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults","volume":"13","author":"Reger","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0560","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/j.peptides.2006.03.036","article-title":"Neurotensin receptor levels as a function of brain aging and cognitive performance in the Morris water maze task in the rat","volume":"27","author":"Rowe","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0565","doi-asserted-by":"crossref","first-page":"35763","DOI":"10.1074\/jbc.M801353200","article-title":"X11 proteins regulate the translocation of amyloid beta-protein precursor (APP) into detergent-resistant membrane and suppress the amyloidogenic cleavage of APP by beta-site-cleaving enzyme in brain","volume":"283","author":"Saito","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0570","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1530\/JOE-20-0439","article-title":"Neurotensin receptor 1 agonist provides neuroprotection in pre-diabetic rats","volume":"248","author":"Saiyasit","year":"2021","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114187","article-title":"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics","volume":"180","author":"Salameh","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107813","article-title":"Neuroprotective and restorative properties of the GLP-1\/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease","volume":"162","author":"Salles","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0585","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0590","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12974-019-1599-9","article-title":"Interleukin 1 alpha administration is neuroprotective and neuro-restorative following experimental ischemic stroke","volume":"16","author":"Salmeron","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0595","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.dadm.2014.11.014","article-title":"Behavioral testing affects the phenotypic expression of APOE \u03b53 and APOE \u03b54 in targeted replacement mice and reduces the differences between them","volume":"1","author":"Salomon-Zimri","year":"2015","journal-title":"Alzheimers Dement (amst)"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0600","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0605","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0610","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/ncb2131","article-title":"CSPalpha promotes SNARE-complex assembly by chaperoning SNAP-25 during synaptic activity","volume":"13","author":"Sharma","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0615","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.731483","article-title":"Liraglutide Improves Cognitive and Neuronal Function in 3-NP Rat Model of Huntington's Disease","volume":"12","author":"Shawki","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0620","doi-asserted-by":"crossref","first-page":"15374","DOI":"10.1074\/jbc.M113.541003","article-title":"Mint proteins are required for synaptic activity-dependent amyloid precursor protein (APP) trafficking and amyloid \u03b2 generation","volume":"289","author":"Sullivan","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0625","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.brainres.2017.10.012","article-title":"Neuroprotective effects of a triple GLP-1\/GIP\/glucagon receptor agonist in the APP\/PS1 transgenic mouse model of Alzheimer's disease","volume":"1678","author":"Tai","year":"2018","journal-title":"Brain Res."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0630","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2217\/nmt.13.73","article-title":"Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs","volume":"4","author":"Talbot, k.","year":"2014","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0635","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jalz.2013.12.007","article-title":"The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease","volume":"10","author":"Talbot","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0640","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0645","article-title":"Aducanumab: evidence from clinical trial data and controversies. drugs","volume":"10","author":"Tampi","year":"2021","journal-title":"Context"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0650","doi-asserted-by":"crossref","first-page":"e3384","DOI":"10.1002\/dmrr.3384","article-title":"Enzymatically stable analogue of the gut-derived peptide xenin on beta-cell transdifferentiation in high fat fed and insulin-deficient Ins1(Cre\/+) ;Rosa26-eYFP mice","volume":"37","author":"Tanday","year":"2021","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0655","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1523\/JNEUROSCI.2262-14.2015","article-title":"Centrally Delivered BACE1 inhibitor activates microglia, and reverses amyloid pathology and cognitive deficit in Aged Tg2576 mice","volume":"35","author":"Thakker","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0660","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1037\/0735-7044.120.5.1093","article-title":"Microinfusions of neurotensin antagonist SR 48692 within the nucleus accumbens core impair spatial learning in rats","volume":"120","author":"Tirado-Santiago","year":"2006","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0665","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10753-020-01344-4","article-title":"GLP-1R Agonist Liraglutide Attenuates Inflammatory Reaction and Neuronal Apoptosis and Reduces Early Brain Injury after Subarachnoid Hemorrhage in Rats","volume":"44","author":"Tu","year":"2021","journal-title":"Inflammation"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0670","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13195-021-00927-z","article-title":"The Alzheimer's disease drug development landscape","volume":"13","author":"van Bokhoven","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0675","article-title":"Lecanemab in Early Alzheimer's Disease","author":"van Dyck","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.neuroscience.2026.01.038_b0680","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13195-014-0089-7","article-title":"BACE1 inhibitor drugs in clinical trials for Alzheimer\u2019s disease","volume":"6","author":"Vassar","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0685","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1212\/01.wnl.0000311269.57716.63","article-title":"Protective effects of NSAIDs on the development of Alzheimer disease","volume":"70","author":"Vlad","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0690","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JAD-141506","article-title":"Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis","volume":"44","author":"Wang","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0695","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.nbd.2003.08.009","article-title":"Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice","volume":"14","author":"Wang","year":"2003","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0700","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eplepsyres.2018.03.009","article-title":"Post-treatment with the GLP-1 analogue liraglutide alleviate chronic inflammation and mitochondrial stress induced by Status epilepticus","volume":"142","author":"Wang","year":"2018","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0705","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2337\/db11-1451","article-title":"Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes","volume":"61","author":"Wice","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0710","doi-asserted-by":"crossref","first-page":"19842","DOI":"10.1074\/jbc.M110.129304","article-title":"Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism","volume":"285","author":"Wice","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0715","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s40001-023-01512-w","article-title":"The FDA-approved anti-amyloid-\u03b2 monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Wu","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0720","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1523\/JNEUROSCI.0408-14.2014","article-title":"Activation of neurotensin receptor 1 facilitates neuronal excitability and spatial learning and memory in the entorhinal cortex: beneficial actions in an Alzheimer's disease model","volume":"34","author":"Xiao","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0725","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2174\/138920101606150407112319","article-title":"New developments of clinical trial in immunotherapy for Alzheimer's disease","volume":"16","author":"Yang","year":"2015","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0730","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1242\/dev.065540","article-title":"ApoE is required for maintenance of the dentate gyrus neural progenitor pool","volume":"138","author":"Yang","year":"2011","journal-title":"Development"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0735","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pbb.2015.10.009","article-title":"DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP\/PS1 transgenic mice","volume":"139","author":"Yang","year":"2015","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0740","article-title":"Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon-like peptide-1 receptor agonists","author":"Yassine","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0745","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00210-013-0918-4","article-title":"FLZ inhibited gamma-secretase selectively and decreased Abeta mitochondrial production in APP-SH-SY5Y cells","volume":"387","author":"Ye","year":"2014","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0750","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3233\/JAD-201262","article-title":"DAla2-GIP-GLU-PAL protects against cognitive deficits and pathology in APP\/PS1 mice by inhibiting neuroinflammation and upregulating cAMP\/PKA\/CREB signaling pathways","volume":"80","author":"Yuan","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0755","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1517\/14740338.2014.914168","article-title":"Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine","volume":"13","author":"Zemek","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0760","article-title":"Neurotensinergic excitation of dentate gyrus granule cells via galphaq-coupled inhibition of TASK-3 channels","author":"Zhang","year":"2014","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neuroscience.2026.01.038_b0765","doi-asserted-by":"crossref","first-page":"G1347","DOI":"10.1152\/ajpgi.00116.2012","article-title":"Xenin-25 increases cytosolic free calcium levels and acetylcholine release from a subset of myenteric neurons","volume":"303","author":"Zhang","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.neuroscience.2026.01.038_b0770","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s12264-018-00336-7","article-title":"Liraglutide ameliorates hyperhomocysteinemia-induced alzheimer-like pathology and memory deficits in rats via multi-molecular targeting","volume":"35","author":"Zhang","year":"2019","journal-title":"Neurosci. Bull."}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226000758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226000758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:05:05Z","timestamp":1773939905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452226000758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":154,"alternative-id":["S0306452226000758"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.01.038","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic efficacy of synthetic analogues of gut hormones in a mouse model of Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.01.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Brain Research Organization (IBRO).","name":"copyright","label":"Copyright"}]}}